Study of Maraviroc-Containing Regimens for HIV PrEP in U.S. Women: HPTN 069/ACTG A5305 Phase II Study

HPTN 069/ACTG A5305 is a Phase II study evaluating the safety and tolerability of Maraviroc (MVC)-containing regimens compared to Tenofovir/emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP) in at-risk women. The study involves a randomized, double-blind, placebo-controlled design with

0 views • 18 slides